间质性肺疾病相关第3组肺动脉高压:诊断困境与治疗难题
间质性肺疾病(ILD)相关肺动脉高压(PH-ILD)可增加补氧需求、降低活动能力并缩短生存期,但症状与无PH的ILD重叠,诊断需高度怀疑。超声心动图是常用筛查工具但敏感性和特异性不足,右心导管仍是确诊金标准。补氧和利尿剂治疗争议小,肺血管扩张剂治疗虽有争议,但INCREASE试验(吸入曲前列尼尔)似乎验证了该治疗概念。
要点
- PH-ILD增加补氧需求、降低活动能力并缩短生存期,诊断需高度怀疑。
- 超声心动图筛查敏感性和特异性不足,右心导管是确诊金标准。
- 补氧和利尿剂治疗争议小,肺血管扩张剂治疗仍存争议但INCREASE试验支持其概念。
核心结论
- PH-ILD与补氧需求增加、活动能力下降和生存期缩短相关,诊断需高度怀疑。
- 右心导管是确诊PH-ILD的金标准,肺血管扩张剂治疗虽存争议但INCREASE试验似乎验证了其概念。
主要发现
- PH-ILD可并发于多种ILD,包括特发性肺纤维化、慢性过敏性肺炎和非特异性间质性肺炎。
- 严重降低的弥散功能或6分钟步行距离、显著的运动性血氧饱和度下降和运动后心率恢复受损均提示PH-ILD。
- 传统经胸超声心动图是PH-ILD最常用的筛查试验,但缺乏敏感性和特异性。
- 右心导管仍是确诊PH-ILD的金标准。
- INCREASE试验(吸入曲前列尼尔)似乎验证了用肺血管扩张剂治疗PH-ILD的概念。
临床怎么用
- 对ILD患者应高度怀疑PH-ILD,关注补氧需求增加、活动能力下降和生存期缩短等表现。
- 可用严重降低的弥散功能或6分钟步行距离、显著运动性血氧饱和度下降和运动后心率恢复受损提示PH-ILD。
- 传统经胸超声心动图筛查敏感性和特异性不足,确诊需行右心导管检查。
- 补氧和利尿剂治疗争议小,肺血管扩张剂治疗需权衡争议,INCREASE试验支持吸入曲前列尼尔的概念。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary hypertension (PH) due to interstitial lung disease (ILD; PH-ILD) can complicate a multitude of ILDs, including idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonitis, and nonspecific interstitial pneumonia. Development of PH-ILD is associated with increased need for supplemental oxygen, reduced mobility, and decreased survival. A high index of suspicion is required to make the diagnosis, given the substantial overlap in symptoms with those of ILD without PH. Severely reduced diffusing capacity or 6-min walk test distance, prominent exertional desaturation, and impaired heart rate recovery after exercise are all suggestive of the development of PH-ILD. Traditional transthoracic echocardiography is the most commonly used screening test for PH-ILD, but it lacks sensitivity and specificity. Newer echocardiographic tools involving 3-dimensional assessment of the right ventricle may have a role in both prognosis and the monitoring of patients with PH-ILD. Right-sided heart catheterization remains the gold standard for confirming a diagnosis of PH-ILD. Although there is little debate about the use of supplemental oxygen and diuretic therapy in the treatment of PH-ILD, treatment with pulmonary vasodilator therapy remains controversial. Although several studies have been terminated prematurely for harm, the recently completed INCREASE trial of inhaled treprostinil appears to validate the concept of treating PH-ILD with pulmonary vasodilators and, we hope, will serve as a foundation from which future studies can be developed.
引用
- King CS, Shlobin OA. The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. Chest. 2020. PMID: 32387520. doi:10.1016/j.chest.2020.04.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。